Tg Therapeutics (TGTX) Equity Average (2011 - 2026)

Tg Therapeutics' Equity Average history runs 16 years deep, the most recent figure standing at $615.6 million for Q1 2026.

• In Q1 2026, Equity Average rose 167.84% year-over-year to $615.6 million; the TTM figure through Mar 2026 stood at $615.6 million (up 167.84% YoY), while the FY2025 annual figure was $435.2 million, up 127.33% from the prior year.
• Equity Average was $615.6 million for Q1 2026 at Tg Therapeutics, down from $627.6 million in the prior quarter.
• In the past five years, Equity Average ranged from a high of $627.6 million in Q4 2025 to a low of $33.9 million in Q2 2023.
• Historically, Equity Average has averaged $222.5 million across 5 years, with a median of $168.8 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Equity Average plunged 78.89% in 2023, then soared 397.42% in 2024.
• A 5-year view of Equity Average shows it stood at $79.5 million in 2022, then surged by 104.49% to $162.6 million in 2023, then rose by 27.44% to $207.3 million in 2024, then soared by 202.82% to $627.6 million in 2025, then fell by 1.92% to $615.6 million in 2026.
• The last three Equity Average figures came in at $615.6 million (Q1 2026), $627.6 million (Q4 2025), and $441.8 million (Q3 2025), per Business Quant data.